Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis

Pembrolizumab is an immune checkpoint inhibitor (ICI) that targets the programmed cell death (PD)-1 receptor. It significantly increases the overall survival in patients with locally advanced or metastatic urothelial cancer. However, its administration may induce serious immune-related adverse effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Akiko, Yokoyama, Minato, Tsuji, Hiroshi, Fujii, Yasuhisa, Tamaoka, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082602/
https://www.ncbi.nlm.nih.gov/pubmed/32211521
http://dx.doi.org/10.1016/j.ensci.2020.100236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082602/
https://www.ncbi.nlm.nih.gov/pubmed/32211521
http://dx.doi.org/10.1016/j.ensci.2020.100236

Ejemplares similares